Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04314440
Other study ID # REB15-100
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 2016
Est. completion date December 2020

Study information

Verified date March 2020
Source Saskatchewan Health Authority - Regina Area
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Several positive physiological and behavioural outcomes have been observed in preterm infants exposed to music therapy during their stay at Neonatal Intensive Care Units (NICU). There is ample evidence in the literature showing that brief exposure to music can lead to superior performance on a host of cognitive tasks in laboratory settings in children, adolescent and adults. However, till date no study has examined the cognitive benefits of NICU music therapy in preterm infants. Further habituation tests have been employed to examine cognitive functioning in infants in laboratory setting but the same test have not been employed as a measure to examine early cognitive functioning in preterm infants.

This project will be carried out to examine the benefits of NICU music therapy on the cognitive functioning of preterm infants born at 27- 33 weeks of gestational age. A randomized controlled research design will be employed to compare cognitive functioning between the treatment and control group at 18 - 24 months of corrected gestational age. The treatment group will be exposed to music therapy during their stay in NICU and the controlled group will be exposed to all standardized care available at our institution except music therapy. Habituation tests will be used to examine cognitive functioning of the preterm infants in groups at 18 - 24 months of gestational age.


Description:

Following previous research, our hypothesis is that infants in the experimental group will display significantly more positive scores on a collection of physiological and behavioural measurements. The stimuli used at each age will be targeted to the infants' developmental level. Bayley Scales of Infant Development will also be administered at 18 - 24 months as part of high risk infant follow up. These data will be included in the analysis for outcome measurement. While seated in a high-chair or their parent's lap, infants will be habituated to a series of images of a particular shape (e.g., a triangle), while their looking time to each stimulus is measured. Each image during habituation will be a unique token of the category (i.e., all different triangles). Habituation will be individually determined, and defined as cumulative looking across three successive trials that is 50% than cumulative looking across the first three trials. Following habituation, infants will be shown a novel token of the habituation shape (e.g., a new triangle) and a novel shape (e.g., a square), in counterbalanced order. If infants recognize the category change, they should look longer at novel category compared to the novel token. For each test, two dependent measures will be sampled: rate of habituation and amount of dishabituation to the novel category. Mixed ANOVA and paired t-tests will be used to analyze the data. As preterm infants have been shown to be delayed on these kinds of tasks, we hypothesize that the experimental group will habituate to each category faster, and/or display stronger dishabituation scores compared to the preterm. We will also use multiple regression analyses to examine relations between the NICU physiological and behavioural measures and the cognitive measures. We hypothesize that infants who most strongly benefited from their therapies in the NICU will display the most advanced cognitive abilities. An intention-to-treat- analysis will be performed for cognitive measures as well. The cognitive assessment at 2 and 4 months that were to be carried out at the Developmental Lab at University of Regina is now canceled due to feasibility concerns.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 102
Est. completion date December 2020
Est. primary completion date December 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 27 Weeks to 33 Weeks
Eligibility Inclusion Criteria:

1. Gestation age 27-33 weeks (maternal dates or early fetal ultrasound)

2. Is not on ventilators

3. Written informed consent forms has been signed from the infant's legal guardian

Exclusion Criteria:

1. Infants with congenital abnormalities

2. Severe intraventricular hemorrhage, with ventriculomegaly or parenchymal hemorrhage

3. Infants with known or suspected prenatal exposure to substance

4. Infants receiving palliative care at NICU

5. Infants who are on ventilators

6. Infants whose legal guardian did not sign the consent forms

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Music therapy
An accredited music therapist will deliver 15-20 minutes of music therapy every day, 4-5 days in week one and remaining in week two to all MT participants. All participants in music therapy group will get a total of nine sessions. The lullaby "twinkle twinkle little star" will be sung for ~5 minutes, followed by the same songs played on acoustic guitar for ~5 minutes and another ~5 minutes of the same song sung in voice. This protocol will be followed in all 9 sessions for all infants in the experimental arm. The sound levels will be maintained at 55-65 decibels (dB) using appropriate meters. If MT is interrupted within 10 minutes then a make-up session will be delivered, assuming no discharge. In case of missed sessions and interrupted session infants will receive a maximum of 12 session.

Locations

Country Name City State
Canada Regina General Hospital, Neonatal Intensive Care Unit, Deaprtment of Pediatrics Regina Saskatchewan

Sponsors (2)

Lead Sponsor Collaborator
Saskatchewan Health Authority - Regina Area University of Regina

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Other outcomes Average difference in weight gain (total calorie intake) between experimental and control group Baseline to 3 weeks when music therapy is complete
Other Other outcome Average difference in length of hospitalization between experimental group and control group Baseline
Other Other outcome Average difference in neurological assessment score between experimental group and control group Baseline
Other Other outcome Average difference in hearing assessment between experimental group and control group Baseline
Primary Time looking at a familiar stimulus Average difference in rate of habituation as measure by the time looking at a familiar stimulus in mili-seconds between experimental and control groups. 18 - 24 months
Secondary Physiological measure Average difference in heart rate before music therapy to after music therapy from before to during and from during to after music therapy. 15 minutes,before, during, after music therapy, 6 days a week
Secondary Physiological measure Average difference in breathing rate before music therapy to after music therapy from before to during and from during to after music therapy. 15 minutes,before, during, after music therapy, 6 days a week
Secondary Physiological measure Average difference in oxygen saturation before music therapy to after music therapy from before to during and from during to after music therapy. 15 minutes,before, during, after music therapy, 6 days a week
Secondary Behavioral measure Difference in sleep between experimental and control group Before to after music therapy 6 days a week
Secondary Behavioral measure Difference in apnea between experimental and control group Before to after music therapy 6 days a week
Secondary Behavioral measure Difference in Bradycardia (number and severity) between experimental and control group Before to after music therapy 6 days a week
Secondary Behavioral measure Difference in de-saturation degree of it between experimental and control group Before to after music therapy 6 days a week
See also
  Status Clinical Trial Phase
Completed NCT02231801 - Monitoring of Vital Signs During Skin-to-skin Holding by Mothers of Their Preterm Babies N/A
Completed NCT01450436 - Impact of Preterm Body Composition at Discharge on 2 Years Neurological Development (ASQ Evaluation)
Completed NCT02268968 - Use of Topical Lidocaine to Reduce Pain in Preterm Infants Receiving Nasal CPAP Continuous Positive Airway Pressure Phase 1
Completed NCT02073071 - Effects of Infant Formula on the Growth and Tolerance in Preterm/Low Birth Weight Infants N/A
Withdrawn NCT02224859 - Invictus Medical, Medical Cranial Support Device (CSD) is a Device Safety Study in Infants at Risk of Head Ulcers. N/A
Completed NCT01944956 - Swallowing Sound in Preterm Infant Evaluation of Feeding Maturation N/A
Terminated NCT02040909 - Optimizing Propofol Dosing for (Preterm) Newborn Infants That Need Endotracheal Intubation Phase 1
Not yet recruiting NCT01772927 - Clinical Tolerance of Numeta 13% N/A
Completed NCT00233324 - Surfactant Positive Airway Pressure and Pulse Oximetry Trial Phase 3
Completed NCT02192996 - Probiotic Supplementation to Improve the GUT Microbiota of Very Low Birth Weight Preterm, a Pilot Study Phase 0
Completed NCT02404623 - The Effect of Vitamin D Administration to Premature Infants on Vitamin D Status and Respiratory Morbidity N/A